Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland - Archive ouverte HAL Access content directly
Journal Articles Journal of The American Academy of Dermatology Year : 2018

Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland

(1) , (2) , (1) , (2) , (3, 4, 5) , (6, 7) , (2)
1
2
3
4
5
6
7

Abstract

Background: Case reports have suggested an association between dipeptidyl peptidase-4 inhibitors (DPP4is) and development of bullous pemphigoid (BP). Objective: To evaluate the association between DPP4i treatment and development of BP. Methods: We conducted a retrospective 1:2 case-control study, comparing case patients with diabetes and BP with age- and sex-matched control patients with diabetes issued from Swiss (Bern) and French (Marseille) dermatologic departments from January 1, 2014, to July 31, 2016. Results: We collected 61 case patients with diabetes and BP and 122 controls. DPP4is were associated with an increased risk for development of BP (adjusted odds ratio, 2.64; 95% confidence interval, 1.19-5.85; P = .02), with vildagliptin showing the highest adjusted odds ratio (3.57 [95% confidence interval, 1.07-11.84; P = .04]). Stratified analysis showed a stronger association in males and patients age 80 years or older. DPP4i withdrawal and the initiation of first-line treatments led to clinical remission in 95% of cases. Limitations: This was a retrospective study in tertiary referral hospitals. We focused the analysis on DPP4i intake, without analyzing the potential isolated effect of metformin. Conclusions: DPP4is, especially vildagliptin, are associated with an increased risk for development of BP. Their use needs to be carefully evaluated, particularly in high-risk patients, such as males and those age 80 years or older.
Fichier principal
Vignette du fichier
PIIS0190962217328785[1].pdf (176.8 Ko) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01757606 , version 1 (10-04-2018)

Identifiers

Cite

Michael Benzaquen, Luca Borradori, Philippe Berbis, Simone Cazzaniga, Rene Valero, et al.. Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland. Journal of The American Academy of Dermatology, In press, 78 (6), pp.1090 - 1096. ⟨10.1016/j.jaad.2017.12.038⟩. ⟨hal-01757606⟩
112 View
99 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More